S. Wang, H. Cai, D. Mei
{"title":"Research progress on effectiveness and safety of approved coronavirus disease 2019 vaccines","authors":"S. Wang, H. Cai, D. Mei","doi":"10.3760/cma.j.cn114015-20210712-00783","DOIUrl":null,"url":null,"abstract":"Vaccine development and vaccination are the most effective means to prevent and control coronavirus disease 2019 (COVID-19). At present, there are 4 types of COVID-19 vaccines approved for emergency use by the World Health Organization and approved conditionally for marketing and emergency use by State Drug Administration of China, including inactivated vaccine, recombinant protein subunit vaccine, messenger RNA vaccine, and adenovirus vector-based vaccine. Pre-marketing clinical studies show that the vaccines above-mentioned can effectively stimulate the body's immune system to produce antibodies against COVID-19, the overall safety is good. Most of the adverse events after vaccination are mild or moderate. However, COVID-19 vaccination involves a large number and wide range of people, and its safety problems can not be ignored. The medical workers and researchers should be on high alert and conduct long-term monitoring to ensure vaccine safety. Copyright © 2021 by the Chinese Medical Association.","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":"86 1","pages":"370-376"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20210712-00783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
2019冠状病毒病已获批疫苗有效性和安全性研究进展
疫苗研制和接种是预防和控制2019冠状病毒病(COVID-19)的最有效手段。目前,世界卫生组织批准应急使用、中国国家药品监督管理局有条件批准上市和应急使用的新型冠状病毒疫苗共有4种,包括灭活疫苗、重组蛋白亚单位疫苗、信使RNA疫苗和腺病毒载体疫苗。上市前临床研究表明,上述疫苗可有效刺激人体免疫系统产生抗COVID-19抗体,整体安全性较好。接种疫苗后的不良事件大多为轻度或中度。然而,COVID-19疫苗接种涉及的人群数量多、范围广,其安全性问题不容忽视。医务工作者和科研人员应保持高度警惕,长期监测,确保疫苗安全。中华医学会版权所有©2021。
本文章由计算机程序翻译,如有差异,请以英文原文为准。